Morning Briefing
Summaries of health policy coverage from major news organizations
Doubt Cast On Northwest Bio's Brain Cancer Vaccine Trial
Northwest Biotherapeutics tried again, but its experimental treatment for brain cancer still falls short. (Feuerstein, 11/21)
Merck said Monday that it is acquiring Imago BioSciences for $1.35 billion, adding experimental drugs that target bone marrow diseases to its research pipeline. The all-cash deal values Imago at $36 per share, or a 107% premium from its closing price on Friday. (Feuerstein, 11/21)
Four years ago, Hall of Fame quarterback Brett Favre joined forces with a Florida neuroscientist to promote an experimental drug — a nasal spray designed to quickly treat brain injuries from a concussion. (Dilanian and Strickler 11/21)
Lawyers have filed at least nine lawsuits against L’Oreal USA Inc and other makers of hair straightener products since last month's release of a U.S. government study linking frequent use of the products to uterine cancer, according to court records. (Jones, 11/21)
